Subhasish Ganguly

Subhasish Ganguly

Auto-generated profile, based on publicly available information

Subhasish Ganguly

Department of Organon of Medicine and Homoeopathic Philosophy, D.N. De Homoeopathic Medical College and Hospital, West Bengal University of Health Sciences, Government of West Bengal, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2021 in Homeopathy
Verified
Journal Article
Closed access
PDF file
SMShyamal Kumar Mukherjee
Shyamal Kumar Mukherjee
SGSubhasish Ganguly
Subhasish Ganguly
SDSATADAL DAS
SATADAL DAS
KCKalyan Kumar Chatterjee
Kalyan Kumar Chatterjee
KNKisor Kumar Naskar
Kisor Kumar Naskar
SSSubhranil Saha
Subhranil Saha
Introduction There is some evidence that homeopathic treatment has been used successfully in previous epidemics, and currently some countries are testing homeoprophylaxis for the coronavirus disease 2019 (COVID-19) pandemic. There is a strong tradition of homeopathic treatment in India: therefore, we decided to compare three different homeopathic medicines against placebo in prevention of COVID-19 infections. Methods In this double-blind, cluster-randomized, placebo-controlled, four parallel arms, community-based, clinical trial, a 20,000-person sample of the population residing in Ward Number 57 of the Tangra area, Kolkata, was randomized in a 1:1:1:1 ratio of clusters to receive one of three homeopathic medicines (Bryonia alba 30cH, Gelsemium sempervirens 30cH, Phosphorus 30cH) or identical-looking placebo, for 3 (children) or 6 (adults) days. All the participants, who were aged 5 to 75 years, received ascorbic acid (vitamin C) tablets of 500 mg, once per day for 6 days. In addition, instructions on healthy diet and general hygienic measures, including hand washing, social distancing and proper use of mask and gloves, were given to all the participants. Results No new confirmed COVID-19 cases were diagnosed in the target population during the follow-up timeframe of 1 month—December 20, 2020 to January 19, 2021—thus making the trial inconclusive. The Phosphorus group had the least exposure to COVID-19 compared with the other groups. In comparison with placebo, the occurrence of unconfirmed COVID-19 cases was significantly less in the Phosphorus group (week 1: odds ratio [OR], 0.1; 95% confidence interval [CI], 0.06 to 0.16; week 2: OR, 0.004; 95% CI, 0.0002 to 0.06; week 3: OR, 0.007; 95% CI, 0.0004 to 0.11; week 4: OR, 0.009; 95% CI, 0.0006 to 0.14), but not in the Bryonia or Gelsemium groups. Conclusion Overall, the trial was inconclusive. The possible effect exerted by Phosphorus necessitates further investigation. Trial registration: CTRI/2020/11/029265.

19 September 2022 in Homeopathy
Verified
Journal Article
Closed access
PDF file
PGPriyanka Ghosh
Priyanka Ghosh
SGSubhasish Ganguly
Subhasish Ganguly
SMShyamal Kumar Mukherjee
Shyamal Kumar Mukherjee
SDSouvik Dutta
Souvik Dutta
ASAbdur Rahaman Shaikh
Abdur Rahaman Shaikh
SSSubhranil Saha
Subhranil Saha
Introduction Hyperuricemia (HU) is a major health issue in India and across the globe. It increases the disease burden and hampers quality of life. This study was aimed at exploring the effects of individualized homeopathic medicines (IHMs) against placebo in the treatment of HU. Methods This double-blind, randomized, placebo-controlled trial was conducted on 60 patients suffering from HU in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Each patient received either IHMs or identical-looking placebos, along with advice on dietary modifications irrespective of codes. Serum uric acid (SUA) level was the primary outcome measure; the HU quality of life questionnaire (HUQLQ) and the Measure Yourself Medical Outcome Profile version 2 (MYMOP-2) were the secondary outcomes; all measured at baseline, and every month, up to 3 months. Group differences were examined by two-way (split-half) repeated-measures analysis of variance after adjusting for baseline differences. Significance level was set at p ≤0.05, two-tailed. Results The intention-to-treat sample (n = 58) was analyzed. Between-group differences in SUA levels (F 1, 56 = 13.833, p <0.001), HUQLQ scores (F 1, 56 = 32.982, p <0.001) and MYMOP-2 profile scores (F 1, 56 = 23.873, p <0.001) were statistically significant, favoring IHMs against placebos, with medium to large effect sizes. Calcarea carbonica and Pulsatilla nigricans were the most frequently prescribed medicines. No serious adverse events were reported from either of the groups. Conclusion IHMs showed significantly better results than placebos in reducing SUA levels and improving quality of life in patients suffering from HU. Trial registration CTRI/2019/10/021503; UTN: U1111–1241–1431. The trial was conducted as part of the postgraduate thesis of the corresponding author. P.G., S.G., S.K.M., S.D. and A.R.S. contributed to the literature search, study concept, conducting the trial, data collection, data evaluation and drafting the manuscript. S.S.A., N.K.S., P.B., M.K., and S.S. contributed to study design, data interpretation, statistical analysis, and drafting of the manuscript. All the authors reviewed and approved the final manuscript for submission. Received: 25 November 2021 Accepted: 22 March 2022 Article published online: 19 September 2022 © 2022. Faculty of Homeopathy. This article is published by Thieme. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

11 April 2025 in Homeopathy
Verified
Journal Article
Closed access
PDF file
URUrmi Roy
Urmi Roy
RPRajat K. Pal
Rajat K. Pal
SSSubhranil Saha
Subhranil Saha
SASk Monsur Alam
Sk Monsur Alam
MKMunmun Koley
Munmun Koley
LRLex Rutten
Lex Rutten
“Pain, Knee, Motion, Amelioration” in the Extremities chapter of Kent's repertory with 20 enlisted medicines is one of the most frequently encountered rubrics in homeopathy but has not been evaluated systematically. Bayesian statistics resulting in the likelihood ratio (LR) could offer a better evaluation of the enlisted medicines as well as the eligibility of other medicines. An analytical, epidemiological, longitudinal outcome study was conducted in different outpatient departments of D.N. De Homoeopathic Medical College and Hospital, Kolkata, on 1,204 patients over 18 months using ORIDL (Outcome Related to Impact on Daily Living), whose scale ranges from +4 to −4. Results were documented during each follow-up, continuing until the most recent visit at an average of 3 months. The LRs were reported with their corresponding 95% confidence intervals (CIs). Analysis included 1,204 cases with 20 enlisted medicines and 37 not enlisted homeopathic medicines. The prevalence of the rubric “Pain, Knee, Motion, Amelioration” was 18.8%. Among the enlisted ones, the medicines having LR ≥ 1.5 were Calcarea carbonicum LR(+) 1.7 (95% CI: 0.8 to 3.5) and Rhus toxicodendron LR(+) 2.3 (95% CI: 1.7 to 3.1). Some medicines with LR ≥ 1.5 that were not previously enlisted in the rubric were Arnica montana LR(+) 2.0 (95% CI: 0.9 to 4.3), Carbo vegetabilis LR(+) 1.8 (95% CI: 0.8 to 4.0), and Staphysagria macrosperma LR(+) 1.5 (95% CI: 0.5 to 5.0). Overall, the findings corroborated the medicines' listing under the rubric in Kent's repertory. There was substantial evidence to link some of the enlisted medicines with the said rubric. Additional research involving a larger population is needed to address the potential confirmation bias.

19 May 2022 in Homeopathy
Verified
Journal Article
Closed access
PDF file
SGSubhasish Ganguly
Subhasish Ganguly
SMShyamal Kumar Mukherjee
Shyamal Kumar Mukherjee
RPRajat Kumar Pal
Rajat Kumar Pal
SHSakhawat Hossain
Sakhawat Hossain
SSSangita Saha
Sangita Saha
SSSubhranil Saha
Subhranil Saha
The concept of using homeopathic medicines as genus epidemicus in epidemic diseases was originally formulated by Dr. Samuel Hahnemann in Aphorism §241: “…each single epidemic is of a peculiar, uniform character common to all the individuals attacked, and when this character is found in the totality of the symptoms common to all, it guides us to the discovery of the (specific) homeopathic remedy suitable for all the cases…”.[1] Kent affirms that the totality of symptoms of a given epidemic corresponding to the nature of the epidemic disease can be obtained after observing about 20 patients and recording the symptoms of each one. Thus, the pathognomonic symptoms of an epidemic are identified. Repertory analysis would guide to a group of six or seven options known as ‘epidemic remedies’ for that particular epidemic, from which the physician would choose the most suitable after going through the Materia Medica.[2] However, for prophylaxis, a lesser degree of similitude is necessary than for curing: a remedy will not have to be so similar to prevent disease as to cure it.[2] From April to June 2021, during the second wave of the pandemic in India, our team of homeopathic doctors managed over 100 patients with COVID-like illness at the outpatients department of D. N. De Homeopathic Medical College and Hospital, Kolkata, West Bengal. Our approach reflected the views of Hahnemann: a remedy that is capable of quickly checking a disease at its onset should be its best preventive.[3] To arrive at the homeopathic genus epidemicus, a common consensus amongst a group of homeopathy experts was sought for the ongoing epidemic. A number of source books of Materia Medica were consulted to cross-check the salient features of the probable homeopathic remedies.[4] [5] [6] [7] We also took into account the remedies prescribed for outpatients of the hospital who had favorable outcomes, the published papers suggesting a probable genus epidemicus for COVID-19 in different parts of India and elsewhere in the world,[8] [9] [10] [11] [12] [13] as well as the most frequently indicated remedies with favorable outcomes in prognostic factor research.[14] [15] Some medicines emerged as the most likely prophylactic remedies: Bryonia alba, Mercurius solubilis, Arsenicum album, Phosphorus and Pulsatilla nigricans. Following literature searches and conference calls in three consecutive rounds, nine of the 11 experts agreed on Bryonia alba 200cH as the prophylactic remedy, while the other two experts strongly advocated Mercurius solubilis 30cH. Assuming that the second wave of COVID-19 in West Bengal mirrored that of the national picture in India, that second wave is now well past its peak. Though Phosphorus revealed some weakly promising (yet inconclusive) prophylactic effects during the first wave of COVID-19 in West Bengal,[11] the choice of medicine differed during the second wave (as outlined above), predominantly because of certain changes in symptomatology.[16] Our near-unanimous conclusion about using Bryonia alba 200cH as the genus epidemicus in the second wave is also supported by some published[12] and unpublished Indian studies. Epidemics are recognised as specific diseases and treated accordingly.[17] If symptoms change, prophylactic medicines will keep changing.[1] [2] [5] Thus, different medicines may be required every year for different episodes of the same epidemic disease, as was also advocated by Dr. Hahnemann.[6] Different remedies may even be indicated in different geographical locations during a single time-point of an ongoing epidemic: Arsenicum album,[18] Cinchona officinalis [19] or Antimonium tartaricum [8] in different areas of Brazil; Bryonia alba in Spain.[9] Moreover, differing prescribing practices in different parts of the world, the varying methods adopted to identify the genus epidemicus, as well as progressively emerging variants of the virus, are further potential contributors in deciding on a genus epidemicus.[20] Thus different remedies are required for different forms of the same disease, as was also recommended by Dr. Hughes.[17] The above experience shows that homeopathic prophylaxis can not be chosen by the name of the epidemic disease itself: rather it should be based exclusively on the nature of the symptoms of the epidemic disease. Though the symptoms may vary according to different stages of the disease, similar medicines to the initial phase of an epidemic disease are the best specifics. Our consensus work forecasts that the genus epidemicus derived from any epidemic should not be used empirically for subsequent waves of the same epidemic. For each and every wave, genus epidemicus should be derived separately and in an integrated manner after treating a number of cases successfully, recording symptoms from the patients in various ways, referring to all available literature and research, arriving at a consensus among experts and, finally, researching the remedies prospectively using the best suitable research design – either randomized controlled trials or comparative cohort studies – to arrive at a valid and reliable conclusion. Received: 04 November 2021 Accepted: 19 November 2021 Publication Date: 19 May 2022 (online) © 2022. Faculty of Homeopathy. This article is published by Thieme. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany